| Texto completo | |
| Autor(es): Mostrar menos - |
Leao, Matheus de Castro
;
di Piazza, Isabella
;
Caria, Sarah Jorge
;
Broering, Milena Fronza
;
Farsky, Sandra Helena Poliselli
;
Uchiyama, Mayara Klimuk
;
Araki, Koiti
;
Bonjour, Kennedy
;
Cogliati, Bruno
;
Pohlmann, Adriana Raffin
;
Guterres, Silvia Staniscuaski
;
Castro, Inar Alves
Número total de Autores: 12
|
| Tipo de documento: | Artigo Científico |
| Fonte: | BIOMEDICINE & PHARMACOTHERAPY; v. 167, p. 10-pg., 2023-09-21. |
| Resumo | |
Background: Omega 3 fatty acids, such as docosahexaenoic acid (DHA) have been widely consumed as supplements to control chronic inflammation. Nanocapsules containing DHA (MLNC-DHA-a1) were developed and showed excellent stability. Thus, our objective was to evaluate the effect of MLNC-DHA-a1 nanocapsules on biomarkers of chronic inflammation. Methods: Cells viability was determined by flow cytometry. The uptake of MLNC-DHA-a1 nanocapsules by macrophages and their polarization were determined. In vivo, LDLr (-,-) mice were fed a Western diet to promote chronic inflammation and were treated with MLNC-DHA-a1 nanocapsules, intravenously injected via the caudal vein once a week for 8 weeks.Results: MLNC-DHA-a1 nanocapsules decreased the concentration of TNF alpha (p = 0.02) in RAW 264.7 cells compared to the non-treated group (NT), with no changes in IL-10 (p = 0.29). The nanocapsules also exhibited an increase in the M2 (F4/80+ CD206) phenotype (p < 0.01) in BMDM cells. In vivo, no difference in body weight was observed among the groups, suggesting that the intervention was well tolerated. However, compared to the CONT group, MLNC-DHA-a1 nanocapsules led to an increase in IL-6 (90.45 x13.31 pg/mL), IL-1 beta (2.76 x1.34 pg/mL) and IL-10 (149.88 x2.51 pg/mL) levels in plasma.Conclusion: MLNC-DHA-a1 nanocapsules showed the potential to promote in vitro macrophage polarization and were well-tolerated in vivo. However, they also increased systemic pro-inflammatory cytokines. Therefore, considering that this immune response presents a limitation for clinical trials, further studies are needed to identify the specific compound in MLNC-DHA-a1 that triggered the immune response. Addressing this issue is essential, as MLNC-DHA-a1 tissue target nanocapsules could contribute to reducing chronic inflammation. (AU) | |
| Processo FAPESP: | 21/02021-1 - Ácido Docosahexaenóico nanoencapsulado com anti-Pecam-1 como estratégia para aumentar a estabilidade da placa aterosclerótica. |
| Beneficiário: | Isabella di Piazza |
| Modalidade de apoio: | Bolsas no Brasil - Iniciação Científica |
| Processo FAPESP: | 19/21029-3 - Ácido docosahexanóico nanoencapsulado com anti-Pecam-1 como estratégia para aumentar a estabilidade da placa aterosclerótica |
| Beneficiário: | Inar Castro Erger |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 21/08196-8 - Efeito do trans-resveratrol na prevenção da placa aterosclerótica |
| Beneficiário: | Sarah Jorge Caria |
| Modalidade de apoio: | Bolsas no Brasil - Iniciação Científica |